NEOGENOMICS INC
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
Dr. David Sholehvar, age 54, was appointed President, Clinical Services Division of the Company, effective March 14, 2022
George A. Cardoza, NeoGenomics, Inc.’s (the “Company”) current President and Chief Operating Officer, Laboratory Operations, informed the Company of his intention to retire from his role effective March 31, 2022.
Dr. Steven Brodie, the Company’s current Senior Vice President, Laboratory Operations, has been appointed the Company’s interim President of Lab Operations.
Extracted from this filing and checked against the source text.
David Sholehvar was appointed as President, Clinical Services Division at NEOGENOMICS INC.
Dr. David Sholehvar, age 54, was appointed President, Clinical Services Division of the Company, effective March 14, 2022View on SEC.gov
George A. Cardoza departed as President and Chief Operating Officer, Laboratory Operations at NEOGENOMICS INC.
George A. Cardoza, NeoGenomics, Inc.’s (the “Company”) current President and Chief Operating Officer, Laboratory Operations, informed the Company of his intention to retire from his role effective March 31, 2022.View on SEC.gov
Steven Brodie was appointed as interim President of Lab Operations at NEOGENOMICS INC.
Dr. Steven Brodie, the Company’s current Senior Vice President, Laboratory Operations, has been appointed the Company’s interim President of Lab Operations.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.